Hanmi Pharm signs anticancer technology export of KRW 1 trillion with Genentech
Hanmi Pharm announced conclusion of a license agreement for the development and commercialization of HM95573, a targeted therapy under development for Phase 1 clinical trials, with an affiliate of Roche, Genentech, on the 29th.
Thus, Genentech now owns the exclusive right to develop and commerci...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
